Bollinger Ingham and Leigh's Trajenta showed positive results

Bollinger Ingham and Riley have published complete data from the CAROLINA trial, which showed no increased cardiovascular risk compared to Glimetin in adults with type 2 diabetes and cardiovascular risk.
The study was the only active comparative cardiovascular results trial for two peptide peptidease-4 (DPP-4) inhibitors, and the longest study of liglitatin safety in the DPP-4 inhibitor cardiovascular results trial, with an average follow-up time of more than six years.in the trial, a higher proportion of patients in the Liglitatin group (16%) reached the secondary compound efficacy endpoint of treatment sustainability, while the Gremethal group had 10.2%. The secondary compound efficacy results that are also met are defined as HbA1c equal to or less than 7% at the time of final consultation, no first aid medication, moderate or severe hypoglycemia or 2% or higher weight gain."The American Diabetes Association and the European Diabetes Research Association recommend type 2 diabetes treatments that are beneficial for people with confirmed cardiovascular disease," said Jeff Emmick, vice president of product development for Lilly Diabetes. "However, doctors considering other therapies to lower blood sugar for patients need an additional drug with established long-term safety," he continued. These new data from CAROLINA, as well as data from the placebo-controlled cardiovascular outcome trial CARMELINA, expand liglitatin's evidence and experience and give medical personnel more confidence in the long-term safety of patients treating a wide range of adult type II patients with Trajenta. Theat the 79th Scientific Conference of the American Diabetes Association in San Francisco. (Compiled by this network)